Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation

World Journal of Gastroenterology

Volumn 18, Issue 16, 2012, Pages 1851-1860

  Tuncer, Hande H ^a,b   Rana, Naveed ^a,b   Milani, Cannon ^a,b   Darko, Angela ^a,b   Al Homsi, Samer A ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Graft versus host disease; Sinusoidal obstruction syndrome; Stem cell transplantation

Indexed keywords

ATROPINE; BUDESONIDE; BUSULFAN; COLESTYRAMINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DIPHENOXYLATE; DRONABINOL; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GRANISETRON; HALOPERIDOL; LOPERAMIDE; LORAZEPAM; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; OCTREOTIDE; ONDANSETRON; OPIATE; PALIFERMIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROCHLORPERAZINE; PROMETHAZINE; TINCTURE OF OPIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACID REFLUX DISEASE; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CANCER RISK; CANDIDA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHOLESTASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TOXICITY; DYSPHAGIA; ENDOSCOPY; ESOPHAGUS STRICTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HERPES SIMPLEX VIRUS; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; IRON OVERLOAD; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; OROPHARYNGEAL MUCOSITIS; PARENTERAL NUTRITION; PATIENT MONITORING; PILL ESOPHAGITIS; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RADIATION DOSE FRACTIONATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; STOMACH ANTRUM VASCULAR ECTASIA; THROMBOCYTE TRANSFUSION; VARICELLA ZOSTER VIRUS; VIRUS HEPATITIS; VIRUS LOAD; WHOLE BODY RADIATION;

EID: 84860467717     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i16.1851     Document Type: Review

References (69)

1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617-1624
2. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, Wen Y, Rapp JA, Kessler J. Clinical applications of bloodderived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008; 299: 925-936
3. FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration. 4th ed. Foundation for the Accreditation of Hematopoietic Cell Therapy. Omaha: Donor Evaluation and Management, 2008: 98-105
4. Confer DL, Miller JP, Chell JW. Bone marrow and peripheral blood cell donors and donor registries. 4th ed. Thomas' Hematopoeitic Cell Transplantation. Oxford: Blackwell Publishing, 2009: 544-554
5. Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002; 11: 215-229
6. Shuhart MC, Myerson D, Childs BH, Fingeroth JD, Perry JJ, Snyder DS, Spurgeon CL, Bevan CA, McDonald GB. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 1994; 84: 3229-3235
7. Peffault de Latour R, Lévy V, Asselah T, Marcellin P, Scieux C, Adès L, Traineau R, Devergie A, Ribaud P, Espérou H, Gluckman E, Valla D, Socié G. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618-1624
8. Hui CK, Lie A, Au WY, Ma SY, Leung YH, Zhang HY, Sun J, Cheung WW, Chim CS, Kwong YL, Liang R, Lau GK. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005; 5: 1437-1445
9. Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingeroth J, Ritz J. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alphainterferon. Transplantation 1996; 62: 1358-1360
10. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 1999; 93: 1127-1136
11. El-Sayed MH, El-Haddad A, Fahmy OA, Salama II, Mahmoud HK. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation. Eur J Gastroenterol Hepatol 2004; 16: 1347-1354
12. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267
13. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol 2005; 39: 75-77
14. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578-1582
15. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049-1059
16. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712
17. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-3153
18. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Kim S, Flowers ME, McDonald GB. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29: 1893-1899
19. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110: 1303-1306
20. Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B, Ramsay NK, Kersey JH, Filipovich A. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-629
21. Roy J, Snover D, Weisdorf S, Mulvahill A, Filipovich A, Weisdorf D. Simultaneous upper and lower endoscopic biopsy in the diagnosis of intestinal graft-versus-host disease. Transplantation 1991; 51: 642-646
22. Trigg ME, Inverso DM. Nausea and vomiting with highdose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant 2008; 42: 501-506
23. Ettinger DS, Armstrong D, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Noonan K, Rugo HS, Siler D, Sorscher SM, Stucky- Marshall L, Torado B, Urba S. Antiemesis. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Version 1.2010. Available from: URL: http//www.nccn.org.
24. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2007; 15: 491-496
25. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs 2004; 20: 30-37
26. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G, Rabitsch W, Urban C, Linkesch W, Neumeister P. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275-279
27. Cox GJ, Matsui SM, Lo RS, Hinds M, Bowden RA, Hackman RC, Meyer WG, Mori M, Tarr PI, Oshiro LS. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994; 107: 1398-1407
28. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674
29. Arango JI, Restrepo A, Schneider DL, Callander NS, Ochoa-Bayona JL, Restrepo MI, Bradshaw P, Patterson J, Freytes CO. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006; 37: 517-521
30. Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant 2002; 30: 517-519
31. Ippoliti C, Champlin R, Bugazia N, Przepiorka D, Neumann J, Giralt S, Khouri I, Gajewski J. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus- host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350-3354
32. Thompson B, Salzman D, Steinhauer J, Lazenby AJ, Wilcox CM. Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: determination of the best diagnostic approach. Bone Marrow Transplant 2006; 38: 371-376
33. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc 1999; 49: 612-621
34. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561
35. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, Davies SM, Blazar BR. Response of 443 patients to steroids as primary therapy for acute graft-versushost disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394
36. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graftversus- host disease. Blood 2007; 109: 4557-4563
37. Nevo S, Swan V, Enger C, Wojno KJ, Bitton R, Shabooti M, Fuller AK, Jones RJ, Braine HG, Vogelsang GB. Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood 1998; 91: 1469-1477
38. Schwartz JM, Wolford JL, Thornquist MD, Hockenbery DM, Murakami CS, Drennan F, Hinds M, Strasser SI, Lopez- Cubero SO, Brar HS, Ko CW, Saunders MD, Okolo CN, McDonald GB. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 2001; 96: 385-393
39. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005; 41: 345-352
40. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic venoocclusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 206-217
41. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010; 51: 1450-1460
42. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108-3114
43. Akpek G, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA, Arai S, Anders V, Vogelsang GB. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903-3907
44. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988; 8: 463-470
45. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, Parkkali T, Hägglund H, Ringdén O. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983
46. Jacobs P, Miller JL, Uys CJ, Dietrich BE. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia. S Afr Med J 1979; 55: 5-10
47. Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG, Woolfrey AE, Shulman HM, Storb R, McDonald GB. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78-84
48. Carreras E, Bertz H, Arcese W, Vernant JP, Tomás JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF. Incidence and outcome of hepatic veno- occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-3604
49. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020
50. Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81: 3458-3462
51. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, Dienes HP, Koerner K, Bunjes D, Arnold R. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998-2004
52. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048
53. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267
54. McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, Schoch HG, McDonald GB. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853-862
55. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31: 599-604
56. Rio B, Andreu G, Nicod A, Arrago JP, Dutrillaux F, Samama M, Zittoun R. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67: 1773-1776
57. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, McDonald GB. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 1015-1022
58. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744
59. Vogelsang GB, Pavletic SZ. Chronic Graft Versus Host Disease: Interdisciplinary Management. 1st ed. New York: Cambridge University Press, 2009
60. Peffault de Latour R, Lévy V, Asselah T, Marcellin P, Scieux C, Adès L, Traineau R, Devergie A, Ribaud P, Espérou H, Gluckman E, Valla D, Socié G. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618-1624
61. Shimizu T, Kasahara M, Tanaka K. Living-donor liver transplantation for chronic hepatic graft-versus-host disease. N Engl J Med 2006; 354: 1536-1537
62. Martin BA, Rowe JM, Kouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant 1995; 15: 145-148
63. Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant 2008; 14: 790-794
64. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003; 101: 91-96
65. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136: 667-672
66. Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, Galimberti M, Giardini C, Gaziev D, Polchi P. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997; 90: 994-998
67. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
68. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, Foretova L, Cocco PL, Staines A, Vornanen M, Whitby D, Boffetta P, Becker N, De Sanjosé S. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006; 131: 1879-1886
69. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101